Iloperidone (Fanapt) vs Paliperidone palmitate (Invega Sustenna)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Paliperidone palmitate (Invega Sustenna)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Partial signal

NCT00101634 · Phase 3 · completed

The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.

Next expected readout: December 2026 · NCT07493551 (registry estimate)

Reported efficacy

Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)

Result source: NCT02431702

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIloperidone (Fanapt)Paliperidone palmitate (Invega Sustenna)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
CGI-S, change—Trial running · NCT06961968-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351
PANSS response—Trial running · NCT06961968—Not posted · NCT00101634
PSP, change—Trial running · NCT069619688.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351
Relapse (% of patients)—Trial running · NCT06961968—Not posted · NCT00101634

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Paliperidone palmitate (Invega Sustenna)
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Sustenna)
-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Sustenna)
8.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Iloperidone (Fanapt): 5 of 5 rows · Paliperidone palmitate (Invega Sustenna): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Paliperidone palmitate (Invega Sustenna)
Rows use multiple source trials
Time to Relapse
time to event · months
NA vs 3.25 placebo months @ 26wka,b,c
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
NA vs NA PP3M months @ 52wka,b,c
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
Dropout rate
34.6%d
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—Part 2-Paliperidone Palmitate (PP)e
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
59.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
6.4%
NCT01081769 · Phase 3 · registry result, not featured evidence
40.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
24.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
44.8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
46.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
48.1%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
28.6%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
14.3%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—d
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—Part 2-Paliperidone Palmitate (PP)e
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
2.2%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—
NCT01081769 · Phase 3 · registry result, not featured evidence
17%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
3.1%
NCT00589914 · Phase 3 · registry result, not featured evidence
8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.3%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Serious AEs
0.7%d
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.8%Part 2-Paliperidone Palmitate (PP)e
NCT02431702 · Phase 3
show 16 more results
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
18.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
5%Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
11.2%
NCT01081769 · Phase 3 · registry result, not featured evidence
6.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
3.9%Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
6.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
—150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
14.3%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
d
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
e
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3
show 16 more results
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3
injection site pain 18.6%
insomnia 18.6%
weight increased 13.3%
NCT01157351 · Phase 4 · registry result, not featured evidence
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
weight increased 15.4%
insomnia 11.2%
headache 10.6%
NCT01081769 · Phase 3 · registry result, not featured evidence
insomnia 17% (placebo 15.2%)
injection site pain 13.2% (placebo 6.7%)
nasopharyngitis 12.6% (placebo 6.1%)
NCT01299389 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.4% (placebo 6.1%)
constipation 5.2% (placebo 5.5%)
insomnia 3.9% (placebo 15.2%)
NCT01299389 · Phase 3 · registry result, not featured evidence
insomnia 9.4%
headache 7.1%
somnolence 5.6%
NCT00589914 · Phase 3 · registry result, not featured evidence
150 mg eq.
injection site pain 8% (placebo 3.7%)
headache 6.1% (placebo 7.3%)
akathisia 5.5% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
100 mg eq.
headache 6.7% (placebo 7.3%)
injection site pain 6.1% (placebo 3.7%)
akathisia 4.8% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
25 mg eq.
headache 10.6% (placebo 7.3%)
injection site pain 8.8% (placebo 3.7%)
akathisia 1.3% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
150 mg
blood prolactin increased 92.9%
insomnia 28.6%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
100 mg
blood prolactin increased 64.3%
psychiatric symptom 42.9%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
150/ 50 mg
blood prolactin increased 71.4%
nasopharyngitis 28.6%
alanine aminotransferase increased 21.4%
NCT01606254 · Phase 2 · registry result, not featured evidence
50 mg
blood prolactin increased 78.6%
nasopharyngitis 35.7%
psychiatric symptom 35.7%
NCT01606254 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: baseline_threshold differs (panss<=100 versus bmi>=17, panss<70); prior_therapy differs (experienced versus none recorded).
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 26 weeks versus 52 weeks.
  4. dPopulation comparability has not been reviewed for 21 of these studies.
  5. ePopulation comparability has not been reviewed for 15 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Paliperidone palmitate (Invega Sustenna)

Time to Treatment Failure NA vs NA Oral Antipsychotics months
time to event · months
NCT02431702 · Phase 3
show 2 more results
NA vs NA Oral Antipsychotics months
NCT02431702 · Phase 3
13.67 vs 7.43 Oral Antipsychotics months*
NCT01157351 · Phase 4 · registry result, not featured evidence · converted to months from 416 days as posted
MCCB Composite 1.6 vs 3.2 Oral Antipsychotics T-score @ 78.2wk
absolute change · T-score
NCT02431702 · Phase 3
show 3 more results
-0.7 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
-0.2 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
2 vs 2.8 Oral Antipsychotics T-score @ 39.1wk
NCT02431702 · Phase 3
PSP 8.3 vs 1.7 placebo score @ 13wk150 mg eq.
absolute change · score
NCT00590577 · Phase 3 · registry result, not featured evidence
show 16 more results
6.1 vs 1.7 placebo score @ 13wk100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.9 vs 1.7 placebo score @ 13wk25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3
5.75 vs 5.36 Oral Antipsychotics score @ 65wk
NCT01157351 · Phase 4 · registry result, not featured evidence
1 vs 1.1 PP3M score @ 52wk
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
4.9 vs 4.3 Oral Antipsychotics score @ 4.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
7.6 vs 7.7 Oral Antipsychotics score @ 13wk
NCT01081769 · Phase 3 · registry result, not featured evidence
9.9 vs 10.8 Oral Antipsychotics score @ 26wk
NCT01081769 · Phase 3 · registry result, not featured evidence
11.4 vs 11.9 Oral Antipsychotics score @ 39wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.7 vs 12.3 Oral Antipsychotics score @ 52wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.9 vs 12.9 Oral Antipsychotics score @ 65wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14 vs 13.3 Oral Antipsychotics score @ 78wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14.7 vs 14 Oral Antipsychotics score @ 91wk
NCT01081769 · Phase 3 · registry result, not featured evidence
15.2 vs 14.6 Oral Antipsychotics score @ 104wk
NCT01081769 · Phase 3 · registry result, not featured evidence
8.5 vs 8.8 RISPERDAL CONSTA score @ 13wk
NCT00589914 · Phase 3 · registry result, not featured evidence
MCCB Working Memory -0.2 vs -0.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-1.7 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Verbal Learning 1.3 vs 1 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.3 vs 0.8 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Speed of Processing 1.8 vs 3.5 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.5 vs 4.9 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Attention/Vigilance 3.2 vs 0.7 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.4 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Visual Learning 1.3 vs 1.4 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.2 vs -0.2 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Reasoning Problem Solving 0.2 vs 2.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
3.4 vs 4.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Social Cognition 0.3 vs 1.6 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-0.2 vs 1.4 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
CGI-S -1 vs 0 placebo score @ 13wk150 mg eq.
absolute change · score
NCT00590577 · Phase 3 · registry result, not featured evidence
show 19 more results
-1 vs 0 placebo score @ 13wk100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
-1 vs 0 placebo score @ 13wk25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
-0.2 vs -0.3 Oral Antipsychotics score
NCT02431702 · Phase 3
-0.7 vs -0.7 Oral Antipsychotics score
NCT02431702 · Phase 3
-0.48 vs -0.43 Oral Antipsychotics score @ 65wk
NCT01157351 · Phase 4 · registry result, not featured evidence
0 vs 0 PP3M score @ 52wk
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
-0.1 vs -0.1 Oral Antipsychotics score @ 1.14wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.3 Oral Antipsychotics score @ 4.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.5 Oral Antipsychotics score @ 8.67wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.6 Oral Antipsychotics score @ 13wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 Oral Antipsychotics score @ 17.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.8 Oral Antipsychotics score @ 26wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 Oral Antipsychotics score @ 39wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1 vs -1 Oral Antipsychotics score @ 52wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 Oral Antipsychotics score @ 65wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1 vs -1 Oral Antipsychotics score @ 78wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1 vs -1.1 Oral Antipsychotics score @ 91wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1.1 vs -1.1 Oral Antipsychotics score @ 104wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 RISPERDAL CONSTA score @ 13wk
NCT00589914 · Phase 3 · registry result, not featured evidence
Time to First Psychiatric Hospitalization or Arrest/Incarceration NA vs 9 Oral Antipsychotics months
time to event · months
NCT01157351 · Phase 4 · registry result, not featured evidence

+ 17 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Paliperidone palmitate (Invega Sustenna)'s landscape